News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Dec 03, 2004
GW is today providing an update on the progress of its regulatory filings for Sativex in the UK and Canada.
Dec 03, 2004
GW hosted a conference call with pharmaceuticals analysts today.
Jun 15, 2004
GW Pharmaceuticals announces positive preliminary results in a Phase III clinical trial with Sativex® in 125 patients with neuropathic (nerve damage) pain.
Jun 09, 2004
The multi centre double blind, randomised, parallel group study in 58 patients assessed the efficacy, safety and tolerability of Sativex®, a whole plant medicinal cannabis extract, compared with placebo for the trea
May 11, 2004
Sativex has been developed by GW and, subject to approval, will be exclusively marketed in Canada by the Pharmaceuticals Division of Bayer HealthCare.
Apr 30, 2004
On 21 January 2004, GW announced that it expected the regulatory assessment process for Sativex to be completed during the second quarter of 2004.
Mar 02, 2004
GW Pharmaceuticals is pleased to announce that, at the Annual General Meeting of the Company held earlier today, all of the resolutions proposed were duly passed.
Jan 21, 2004
GW Pharmaceuticals plc, the company which develops a range of new medicines based on cannabis and other controlled drugs, announces its preliminary results for the year ended 30 September 2003.
Jan 14, 2004
GW announces that it has appointed N M Rothschild & Sons as its financial adviser and Hoare Govett Limited as its Nominated Adviser and broker with immediate effect.